Curasight A/S presents at Økonomisk Ugebrev Life Science Investor Conference

March 5, 2021

Regulatory

Curasight A/S CEO Ulrich Krasilnikoff will present the company and its future plans, at Økonomisk Ugebrev Life Science Investor Conference 10 March 2021. The presentation will be webcasted live.

For more information – please click here

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: [email protected]

www.curasight.com

Downloads

Release

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.